lorviqua
pfizer europe ma eeig - lorlatinib - rak, niedrobnokomórkowe płuca - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
erlotinib sandoz 100 mg tabletki powlekane
sandoz gmbh - erlotinibum - tabletki powlekane - 100 mg
erlotinib sandoz 150 mg tabletki powlekane
sandoz gmbh - erlotinibum - tabletki powlekane - 150 mg
erlotinib sandoz 25 mg tabletki powlekane
sandoz gmbh - erlotinibum - tabletki powlekane - 25 mg
erlotinib vipharm 25 mg tabletki powlekane
vipharm s.a. - erlotinibum - tabletki powlekane - 25 mg
erlotinib vipharm 100 mg tabletki powlekane
vipharm s.a. - erlotinibum - tabletki powlekane - 100 mg
erlotinib vipharm 150 mg tabletki powlekane
vipharm s.a. - erlotinibum - tabletki powlekane - 150 mg
erlotinib glenmark 25 mg tabletki powlekane
glenmark pharmaceuticals s.r.o. - erlotinibum - tabletki powlekane - 25 mg
erlotinib glenmark 100 mg tabletki powlekane
glenmark pharmaceuticals s.r.o. - erlotinibum - tabletki powlekane - 100 mg
erlotinib glenmark 150 mg tabletki powlekane
glenmark pharmaceuticals s.r.o. - erlotinibum - tabletki powlekane - 150 mg